I.V. Asfandiyarova1, L.M. Kutliyarov1, V.S. Shchekin1, A.O. Vlasova1
1Bashkir State Medical University, Ufa
Asfandiyarova I.V. – research resident, resident physician of the Department of Nursing and Palliative Care
Lenin St., 3, Ufa, 450008, Russian Federation, tel.: +7-951-989-99-93, e-mail: i.asfan@mail.ru, ORCID ID: 0000-0003-2760-7454
Abstract. The article presents an overview of current literature data on the use of vaccines in the treatment of bladder cancer (BC). It considers current concepts of the epidemiology and risk factors of BC, as well as the mechanisms of antitumor vaccines’ action aimed at activating a specific immune response against tumor cells. The results of preclinical and clinical studies of various types of vaccines, including BCG, peptide and cellular platforms, are analyzed. The advantages and limitations of vaccine therapy are discussed, as well as its place in existing treatment regimens and the prospects for integration into personalized oncology treatment. The data obtained indicate a high potential of vaccines in BC treatment to increase the therapy effectiveness and improve the prognosis and the patients’ quality of life.
Key words: bladder cancer, cancer vaccine, peptide-based vaccine, dendritic cell-based vaccine, virus-based vaccine, RNA-based vaccine, DNA-based vaccine.